静脉注射免疫球蛋白有助于控制抗MDA5抗体阳性皮肌炎伴掌部紫红色斑丘疹
本文报告3例抗MDA5抗体阳性皮肌炎合并快速进展性间质性肺病(RP-ILD)患者,接受包括大剂量泼尼松龙、他克莫司、静脉环磷酰胺和静脉注射免疫球蛋白(IVIG)的联合治疗。所有3例在IVIG给药后血清铁蛋白水平下降,提示IVIG可能有助于控制疾病活动度;所有3例早期均见指间关节周围掌部紫红色斑丘疹,可能有助于提示抗MDA5抗体相关皮肌炎的诊断。
要点
- 抗MDA5抗体阳性皮肌炎常合并RP-ILD,预后差。
- 3例联合治疗患者IVIG后血清铁蛋白下降。
- 掌部紫红色斑丘疹可能提示抗MDA5抗体相关皮肌炎。
核心结论
- IVIG可能有助于控制抗MDA5抗体阳性皮肌炎的疾病活动度。
研究设计与样本
- 本文报告3例抗MDA5抗体相关皮肌炎合并RP-ILD的病例。
主要发现
- 3例患者均接受大剂量泼尼松龙、他克莫司、静脉环磷酰胺和IVIG联合治疗。
- 所有3例在IVIG给药后血清铁蛋白水平下降。
- 所有3例早期均观察到指间关节周围掌部紫红色斑丘疹。
临床怎么用
- 抗MDA5抗体阳性皮肌炎合并RP-ILD可考虑联合治疗包括IVIG。
- 掌部紫红色斑丘疹可作为提示抗MDA5抗体相关皮肌炎诊断的体征。
局限性
- 仅为3例病例报告,证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoantibodies to melanoma differentiation-associated protein 5 (MDA5) are associated with a subset of patients with dermatomyositis (DM) who have rapidly progressive interstitial lung disease (RP-ILD) with poor prognosis. Intensive immunosuppressive therapy is initiated before irreversible lung damage can occur; however, there are few lines of evidence for the treatment of RP-ILD. Here, we report three cases of anti-MDA5 antibody-associated DM with RP-ILD in which the patients were treated with combined-modality therapy, including high-dose prednisolone, tacrolimus, intravenous cyclophosphamide and intravenous immunoglobulin (IVIG). In all three cases, serum ferritin levels, which are known to represent the disease activity of RP-ILD, were decreased after IVIG administration. IVIG might contribute to the control of the disease activity of anti-MDA5 antibody-positive DM. Moreover, palmar violaceous macules/papules around the interphalangeal joints, which was observed in all three cases in the incipient stage, might be a useful sign in suggesting a diagnosis of anti-MDA5 antibody-associated DM.
引用
- Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017. PMID: 28346662. doi:10.1111/bjd.15499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。